Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000822441 | SCV000963242 | uncertain significance | Immunodeficiency, common variable, 2 | 2023-12-11 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with arginine, which is basic and polar, at codon 156 of the TNFRSF13B protein (p.Ser156Arg). This variant is present in population databases (rs148758686, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with TNFRSF13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 664357). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNFRSF13B protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004029101 | SCV004967859 | uncertain significance | Inborn genetic diseases | 2024-02-27 | criteria provided, single submitter | clinical testing | The c.468T>G (p.S156R) alteration is located in exon 4 (coding exon 4) of the TNFRSF13B gene. This alteration results from a T to G substitution at nucleotide position 468, causing the serine (S) at amino acid position 156 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |